Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy

Centralized before Judge Karen S. Marston in the Eastern District of Pennsylvania in December 2025, this docket consolidates claims that GLP-1 receptor agonist medications caused non-arteritic anterior ischemic optic neuropathy (NAION) — a form of sudden, typically permanent vision loss — in users, a distinct injury theory from the gastroparesis claims proceeding in the separate, larger GLP-1 RAs MDL before the same judge. With 216 actions pending roughly nine months after centralization, this is a comparatively young docket, and the fact that the JPML created a dedicated proceeding for this specific injury theory — rather than folding NAION claims into the existing gastrointestinal-injury MDL — signals that the causation science and expert evidence for vision-loss claims will need to be developed and litigated on their own terms.

For a funder, that separation matters directly: general-causation progress in the sibling GLP-1 gastroparesis MDL will not automatically resolve or even directly inform the causation question specific to NAION, since eye-injury causation involves different medical literature, different biological mechanisms, and likely different expert witnesses than gastrointestinal injury claims. Funding decisions here should be underwritten against this docket's own developing record, not assumed to track the pace or outcome of the larger sibling litigation.

Ophthalmologic documentation — the timing and diagnosis of vision loss relative to drug initiation, and confirmation of the NAION diagnosis itself by an ophthalmologist — is the central underwriting fact for individual claims at this early stage. Given the docket's youth, funding structures should assume a longer duration horizon consistent with a proceeding that has not yet reached case-management maturity, bellwether selection, or any settlement discussion. Criterica Capital's mass tort finance product applies to claims in this docket, and a structural brief distinguishing it from the related GLP-1 gastroparesis MDL is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.